Mark R. Prausnitz
Affiliations: | Chemical Engineering | Georgia Institute of Technology, Atlanta, GA |
Area:
Chemical Engineering, Biomedical Engineering, OphthalmologyWebsite:
https://www.research.gatech.edu/mark-prausnitzGoogle:
"Mark Prausnitz"Bio:
Prausnitz, Mark R Electroporation of tissue and cells for drug delivery applications Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 1994.
Parents
Sign in to add mentor| Robert S. Langer | grad student | 1994 | MIT (Chemistry Tree) | |
| (Electroporation of tissue and cells for drug delivery applications) | ||||
| James C. Weaver | grad student | 1994 | MIT | |
Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dul M, Alali M, Ameri M, et al. (2023) Assessing the risk of a clinically significant infection from a microneedle Array patch (MAP) product. Journal of Controlled Release : Official Journal of the Controlled Release Society |
| Kim Y, Jung JH, Tadros AR, et al. (2023) Tolerability, acceptability, and reproducibility of topical STAR particles in human subjects. Bioengineering & Translational Medicine. 8: e10524 |
| Chen Q, Xiao Z, Wang C, et al. (2022) Microneedle Patches Loaded with Nanovesicles for Glucose Transporter-Mediated Insulin Delivery. Acs Nano |
| Jung JH, Kim SS, Chung H, et al. (2022) Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space. Journal of Controlled Release : Official Journal of the Controlled Release Society |
| Adigweme I, Akpalu E, Yisa M, et al. (2022) Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]. Trials. 23: 775 |
| Jang D, Tang J, Schwendeman SP, et al. (2022) Effect of Surface Interactions on Microsphere Loading in Dissolving Microneedle Patches. Acs Applied Materials & Interfaces |
| Li W, Chen JY, Terry RN, et al. (2022) Core-shell microneedle patch for six-month controlled-release contraceptive delivery. Journal of Controlled Release : Official Journal of the Controlled Release Society |
| Labouta HI, Langer R, Cullis PR, et al. (2022) Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective. Drug Delivery and Translational Research |
| Tang J, Schutzman R, Rodríguez CA, et al. (2021) Coaxial electrospray of uniform polylactide core-shell microparticles for long-acting contraceptive. Journal of Controlled Release : Official Journal of the Controlled Release Society. 341: 634-645 |
| Li S, Xia D, Prausnitz MR. (2021) Efficient Drug Delivery into Skin Using a Biphasic Dissolvable Microneedle Patch with Water-Insoluble Backing. Advanced Functional Materials. 31 |